Innate Pharma (NASDAQ:IPHA) shares fell 17% Wednesday following the release of phase 1 data for its investigational Nectin-4-targeting antibody-drug conjugate IPH4502.
Innate Pharma stock tumbles after phase 1 trial data
view original post
Innate Pharma (NASDAQ:IPHA) shares fell 17% Wednesday following the release of phase 1 data for its investigational Nectin-4-targeting antibody-drug conjugate IPH4502.